{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:25:53Z","timestamp":1751430353386,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05338-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:03:44Z","timestamp":1751375024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Essential thrombocythemia as an initial presentation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with complete response to the bortezomib, cyclophosphamide, dexamethasone regimen: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Alireza","family":"Zangooie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhosein","family":"Maharati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolghasem","family":"Allahyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5338_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-019-0355-6","volume":"19","author":"H Li","year":"2019","unstructured":"Li H, et\u00a0al. Endocrine manifestations in POEMS syndrome: a case report and literature review. BMC Endocr Disord. 2019;19:1\u20137.","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"5338_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ajh.25495","volume":"94","author":"A Dispenzieri","year":"2019","unstructured":"Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(7):812\u201327.","journal-title":"Am J Hematol"},{"issue":"2","key":"5338_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/medicina55020054","volume":"55","author":"G Gadomska","year":"2019","unstructured":"Gadomska G, et\u00a0al. Activation of TF-dependent blood coagulation pathway and VEGF-A in patients with essential thrombocythemia. Medicina (Kaunas). 2019;55(2):54.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"5338_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","volume":"122","author":"MS Humeniuk","year":"2013","unstructured":"Humeniuk MS, et\u00a0al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013;122(1):68\u201373.","journal-title":"Blood"},{"issue":"4","key":"5338_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/anr.1780320411","volume":"32","author":"MJ Dauphin\u00e9e","year":"1989","unstructured":"Dauphin\u00e9e MJ, et\u00a0al. The expression and function of CD3 and CD5 in patients with primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 1989;32(4):420\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5338_CR6","first-page":"859","volume":"10","author":"DM Dorfman","year":"1997","unstructured":"Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol. 1997;10(9):859\u201363.","journal-title":"Mod Pathol"},{"issue":"19","key":"5338_CR7","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3390\/cancers14194917","volume":"14","author":"A Schilhabel","year":"2022","unstructured":"Schilhabel A, et\u00a0al. CD20 expression as a possible novel prognostic marker in CLL: application of EuroFlow standardization technique and normalization procedures in flow cytometric expression analysis. Cancers (Basel). 2022;14(19):4917.","journal-title":"Cancers (Basel)"},{"key":"5338_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1746-1596-6-33","volume":"6","author":"VK Prevodnik","year":"2011","unstructured":"Prevodnik VK, et\u00a0al. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011;6:33.","journal-title":"Diagn Pathol"},{"issue":"6","key":"5338_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.10401","volume":"94","author":"F DiRaimondo","year":"2002","unstructured":"DiRaimondo F, et\u00a0al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002;94(6):1721\u201330.","journal-title":"Cancer"},{"issue":"6","key":"5338_CR10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/ajcp\/87.6.708","volume":"87","author":"KD Shah","year":"1987","unstructured":"Shah KD, Tabibzadeh SS, Gerber MA. Comparison of cytokeratin expression in primary and metastatic carcinomas. Diagnostic application in surgical pathology. Am J Clin Pathol. 1987;87(6):708\u201315.","journal-title":"Am J Clin Pathol."},{"issue":"3","key":"5338_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","volume":"41","author":"Y Kawano","year":"2012","unstructured":"Kawano Y, et\u00a0al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876\u201384.","journal-title":"Int J Oncol"},{"issue":"2","key":"5338_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","volume":"127","author":"X Sun","year":"2018","unstructured":"Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127(2):175\u201386.","journal-title":"Chromosoma"},{"issue":"12","key":"5338_CR13","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","volume":"98","author":"A Dispenzieri","year":"2023","unstructured":"Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(12):1934\u201350.","journal-title":"Am J Hematol"},{"issue":"2","key":"5338_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajh.26422","volume":"97","author":"PW Mellors","year":"2022","unstructured":"Mellors PW, et\u00a0al. Characteristics and risk factors for thrombosis in POEMS syndrome: a retrospective evaluation of 230 patients. Am J Hematol. 2022;97(2):209\u201315.","journal-title":"Am J Hematol"},{"issue":"10","key":"5338_CR15","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/bloodadvances.2020001492","volume":"4","author":"Z Sayar","year":"2020","unstructured":"Sayar Z, et\u00a0al. High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Blood Adv. 2020;4(10):2139\u201342.","journal-title":"Blood Adv"},{"issue":"12","key":"5338_CR16","doi-asserted-by":"publisher","first-page":"omac129","DOI":"10.1093\/omcr\/omac129","volume":"2022","author":"E Angeloudi","year":"2022","unstructured":"Angeloudi E, et\u00a0al. A rare case of POEMS syndrome presenting as essential thrombocythemia. Oxf Med Case Rep. 2022;2022(12):omac129.","journal-title":"Oxf Med Case Rep"},{"issue":"2","key":"5338_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-012-1583-2","volume":"92","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, et\u00a0al. Multiple angiogenetic factors are upregulated in POEMS syndrome. Ann Hematol. 2013;92(2):245\u20138.","journal-title":"Ann Hematol"},{"issue":"Pt 8","key":"5338_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/brain\/awh519","volume":"128","author":"M Scarlato","year":"2005","unstructured":"Scarlato M, et\u00a0al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128(Pt 8):1911\u201320.","journal-title":"Brain"},{"issue":"12","key":"5338_CR19","first-page":"3111","volume":"13","author":"Y Du","year":"2020","unstructured":"Du Y, et\u00a0al. JAK\/STAT and VEGF\/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study. Int J Clin Exp Pathol. 2020;13(12):3111\u20139.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"5338_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/ph15020160","volume":"15","author":"MS Bader","year":"2022","unstructured":"Bader MS, Meyer SC. JAK2 in myeloproliferative neoplasms: still a protagonist. Pharmaceuticals (Basel). 2022;15(2):160.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"5338_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.14497","volume":"181","author":"H He","year":"2018","unstructured":"He H, et\u00a0al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol. 2018;181(1):126\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"5338_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","volume":"193","author":"AM Gomez","year":"2014","unstructured":"Gomez AM, et\u00a0al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol. 2014;193(3):1055\u201363.","journal-title":"J Immunol"},{"issue":"1","key":"5338_CR23","doi-asserted-by":"publisher","first-page":"1859263","DOI":"10.1080\/2162402X.2020.1859263","volume":"10","author":"SD Naicker","year":"2021","unstructured":"Naicker SD, et\u00a0al. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021;10(1):1859263.","journal-title":"Oncoimmunology"},{"issue":"4","key":"5338_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, et\u00a0al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80(4):887\u201390.","journal-title":"Blood"},{"issue":"6","key":"5338_CR25","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2010.01544.x","volume":"101","author":"D Tamura","year":"2010","unstructured":"Tamura D, et\u00a0al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2\/M transition. Cancer Sci. 2010;101(6):1403\u20138.","journal-title":"Cancer Sci"},{"key":"5338_CR26","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1182\/blood-2023-185515","volume":"142","author":"P Li","year":"2023","unstructured":"Li P, et\u00a0al. The mechanism underlying lenalidomide-induced thrombosis susceptibility. Blood. 2023;142:6505.","journal-title":"Blood"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05338-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:05:59Z","timestamp":1751418359000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05338-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5338"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05338-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}